TS及EGFR在非小细胞肺癌中表达及其临床意义  

Expressions and clinical significance of TS and EGFR in non-small cell lung cancer

作　　者：江曼[1] 钱晓萍[1] 杨阳[1] 任伟[1] 刘宝瑞[1] 胡静[1] 王立峰[1] 

机构地区：[1]南京大学医学院附属鼓楼医院肿瘤中心,江苏省210008

出　　处：《江苏医药》2014年第11期1289-1291,共3页Jiangsu Medical Journal

摘　　要：目的研究非小细胞肺癌(NSCLC)组织中胸苷酸合成酶(TS)及表皮生长因子受体(EGFR)蛋白的表达及其临床意义。方法免疫组化方法检测431例NSCLC组织中TS及EGFR蛋白表达,评估其与临床病理参数的关系。结果 TS蛋白在NSCLC组织中阳性表达率为35.1%(134/382);其表达水平与肿瘤分化程度及淋巴结转移有关(P<0.05)。EGFR蛋白在NSCLC组织中阳性表达率为74.1%(312/421);其表达水平与病理类型、分化程度及淋巴结转移情况有关(P<0.05)。结论 TS及EGFR蛋白表达与部分临床病理参数相关,对NSCLC诊断及预后的判断可能具有重要价值。Objective To investigate the protein expressions and clinical significance of thymidylate synthase（TS） and epidermal growth factor receptor（EGFR） in human non-small cell lung cancer （NSCI.C）. Methods The protein expressions of TS and EGFR were detected by immunohistochemistry in 431 cases with NSCLC. The relationship between the expressions and clinicopathological characteristics was analyzed. Results The positive expression rates of TS and EGFR in NSCLC were 35.1% （134/382） and 74. 1 % （312/421）, respectively. TS expression was correlated with tumor differentiation and lymph node metastasis（P〈0. 05）, while EGFR expression was correlated with pathological type, tumor differentiation and lymph node metastasis （ P〈0. 05 ）. Conclusion TS and EGFR expressions are associated with part of clinicopathological characteristics, which may play an important role in the diagnosis and prediction of the prognosis of NSCLC patients.

关 键 词：非小细胞肺癌 胸苷酸合成酶 表皮生长因子受体 

分 类 号：R365[医药卫生—病理学]